A three year field study of preconditioning native Illinois beef calves sold through a cooperative marketing association--1969 to 1971.
During the fall of 1969, 1970 and 1971, Central Illinois practitioners preconditioned (PC) 1,576 beef calves at a cost range of $3.02 to $4.72. The PC program included weaning calves 30 days before sale, having calves eating grain from a bunk and drinking from a tank, vaccinated against blackleg, malignant edema, infectious bovine rhinotracheitis (IBR) and bovine parainfluenza virus (PI3). Calves were tagged in the right ear with the green certified preconditioned for health (CPH) tag of the American Association of Bovine Practitioners. Bovine virus diarrhea (BVD) vaccine was added to the program in 1970 and 1971 since clinical cases of the disease occurred in PC calves not receiving the vaccine in 1969. Intranasal PI3 vaccine and Pasteurella hemolytica and multocida bacterin was added to the 1971 program to attempt better immunization. In 1969, more PC than non-preconditioned (NPC) calves were treated for acute respiratory disease after sale. The 1970 study showed that fewer PC than NPC calves were treated for acute respiratory tract disease. The 1971 finding showed the greatest differences. A comparison of 389 PC and 227 NPC calves sold at auction in 1971 and moved into the same feedlots showed a statistically significant reduction in number of cases of acute respiratory tract disease treated in PC calves. Generally, PC calves sold at a higher price than NPC calves.
D000818:Animals; D001408:Bacillus anthracis / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000517:prevention & control; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy / Q000517:prevention & control*; D003013:Clostridium / Q000276:immunology; D003365:Costs and Cost Analysis; D007087:Illinois; D007241:Infectious Bovine Rhinotracheitis / Q000276:immunology; D009349:Nematode Infections / Q000662:veterinary; D010325:Pasteurella / Q000276:immunology; D012328:RNA Viruses / Q000276:immunology; D013827:Thiabendazole / Q000627:therapeutic use; D014765:Viral Vaccines / Q000008:administration & dosage; D014886:Weaning
D001428:Bacterial Vaccines; D014765:Viral Vaccines; D013827:Thiabendazole